2,3-Diaminopyridine Pharma Grade API, supplied under the manufacturer-specific model designation 2,3-DAP-PG, is a crystalline drug substance with molecular formula C₅H₇N₃ and CAS Registry Number 452-58-4. The molecular mass is 109.13 g/mol. The material is controlled for use in oral solid dosage forms—tablets, capsules, and granules—and in injectable preparations where downstream aseptic processing or terminal sterilization is supported by validated stability data. No harmonized pharmacopoeial monograph for this exact positional isomer is published in the major compendia; release therefore follows the ICH Q6A decision tree with validated in-house high-performance liquid chromatography, infrared spectrophotometry, and residual solvent procedures. The pharma grade differs from technical-grade material primarily by a lower bacterial endotoxin limit, a restricted residual solvent profile aligned with ICH Q3C, and an impurity panel that controls the 2,6- and 3,4-isomers and related pyridine by-products.

The API is not a finished dosage form. It is incorporated into tablets, capsules, granules, or injectable formulations only after excipient compatibility, forced degradation, and process validation. For solid oral dosage forms, the material can be blended by direct compression or granulated by high-shear wet processing. A representative oral grade may show D90 below 100 µm and bulk density in the range 0.45–0.60 g/cm³, but these values are lot-specific and must be confirmed against the manufacturer's certificate of analysis because no universal compendial particle-size limit exists. Pre-drying is required when ambient relative humidity exceeds 60%, as moisture uptake can reduce flow and cause caking in hopper feed systems. The primary amine functionalities react with reducing sugars and aldehydes; therefore, lactose-based wet granulation requires a compatibility study under 40°C/75% RH for 4 weeks before scale-up. For capsule filling, poor flow may require roller compaction or slugging. If colloidal silicon dioxide is used as a glidant, addition levels above 0.5% w/w can reduce blend compressibility and increase ejection force on single-station tablet presses.

Specification Panel and Analytical Reference Limits

Representative release criteria for the pharma grade are summarised below. Actual limits are manufacturer-specific and should be verified against the active drug master file or active substance master file. When a single API is used for oral and injectable products, the stricter injectable specification should govern release for microbial quality and endotoxin.

For granules intended for sachet or capsule filling, fluid-bed granulation with an aqueous binder can be used when the API is pre-mixed with a hydrophilic filler. Granulation end-point should be monitored by impeller torque or power consumption rather than time alone; over-granulation increases the fraction of large agglomerates and reduces dissolution rate. The API’s amine groups can interact with acidic excipients such as citric acid. If an acidulant is required for a buffered or taste-masked formulation, a compatibility study under 40°C/75% RH for 4 weeks should be conducted to rule out salt formation or hygroscopicity collapse. The dried granulation should lie between 1.0% and 3.0% residual moisture before compression; a tablet tensile strength above 1.5 MPa and friability below 1.0% in accordance with USP <1216> are typical development targets for immediate-release tablets.

Aseptic manufacturing of injectable dosage forms from 2,3-DAP-PG imposes a different control space. Bacterial endotoxin must be below 0.05 EU/mg, total aerobic microbial count must be controlled, and processing water must meet WFI compendial standards. Terminal sterilization at 121°C for 15 minutes may be acceptable only when supported by stress studies and pH-buffering selection; the aromatic amine is susceptible to oxidative discoloration when solution pH exceeds 7.5, so nitrogen-blanketed preparation and storage under vacuum are advised. If aseptic filtration is used, a 0.22 µm PVDF or PES membrane is preferred; nylon membranes are not recommended because the aminopyridine ring may adsorb to polyamide surfaces. For lyophilized injection, the collapse temperature must be established by freeze-drying microscopy; published data for this specific isomer is limited, so development lots require differential scanning calorimetry and residual moisture mapping. The API should be protected from light and stored in amber glass or double LDPE bags inside HDPE drums at 15–25°C.

Why Is Regiochemistry a Control Rather Than a Cosmetic Variation?

2,3-Diaminopyridine is a positional isomer of 3,4-diaminopyridine and 2,6-diaminopyridine. The three isomers share the same molecular formula and molecular mass, but the orientation of the amino groups changes the electronic environment of the pyridine ring, the ability to form hydrogen-bonded networks, and the interaction with polar excipients and metal surfaces. The 2,3-isomer has adjacent amino groups that can act as bidentate coordination sites; this requires the final synthetic step to exclude transition-metal catalysts and to control metal residues below the ICH Q3D limit for parenteral products. By contrast, 3,4-diaminopyridine is the active substance in amifampridine formulations for Lambert-Eaton myasthenic syndrome and has a distinct clinical and regulatory identity. 2,6-Diaminopyridine is primarily used as a synthetic intermediate and is not interchangeable with the 2,3-isomer in a licensed drug product. Batch records must therefore confirm positional isomer identity by infrared spectroscopy and a chromatographic method capable of resolving the three diaminopyridine isomers.

When a Single API Grade Must Serve Oral and Injectable Routes

If a manufacturer uses one API grade for both oral and injectable products, the injectable specification should govern release for bacterial endotoxin, microbial enumeration, and particulate matter. A dual-grade program can reduce inventory complexity but creates a conflict because oral solid dosage manufacturing often tolerates a higher bioburden and wider particle-size distribution. The conflict is resolved by applying the parenteral acceptance criterion of ≤0.05 EU/mg to every lot, even when the lot is intended only for tablet or capsule manufacture. This approach increases testing cost but prevents cross-contamination of a non-controlled lot into sterile production. In addition, the residual solvent profile must be re-evaluated for each route; solvents accepted for oral use under ICH Q3C may require tighter limits if the injectable product is manufactured with the same solvent-laden API. The cleaning validation matrix should separate oral and injectable equipment trains; use of shared granulators or bins without dedicated validation invites cross-contact with non-sterile powders and is discouraged.

The primary aromatic amine groups of 2,3-diaminopyridine are sensitive to nitrous acid; exposure to nitrite can form diazonium intermediates, with potential genotoxic impurities. Secondary amine impurities, if present, require a nitrosamine risk assessment under ICH M7. Nitrite-containing cleaning solutions, acidic process waters with nitrate reduction, and nitroso-containing excipients must be excluded from all stages of drug product manufacture. The API should be stored away from strong oxidising agents, acid chlorides, and reducing sugars. If a tablet or capsule formulation requires a reducing sugar or an aldehyde-based flavoring agent, the compatibility data must demonstrate no Schiff base formation and no increase in related substances beyond the specified limit. The API is not intentionally sterile; injectable formulations require further aseptic processing or terminal sterilization. Published data for this specific isomer in parenteral formulations is limited; therefore, each manufacturer should generate in-use stability data in the intended diluent and primary packaging.